MxB is not responsible for the blocking of HIV-1 infection observed in alpha interferontreated cells

Journal of Virology

Volumn 90, Issue 6, 2016, Pages 3056-3064

  Opp, Silvana ^a   Vieira, Daniel A S A ^a   Schulte, Bianca ^a   Chanda, Sumit K ^b   Diaz Griffero, Felipe ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MYXOVIRUS RESISTANCE PROTEIN; MYXOVIRUS RESISTANCE PROTEIN B; NEVIRAPINE; UNCLASSIFIED DRUG; MX2 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS INHIBITION; CELL LINE; GENE INACTIVATION; GENETICS; IMMUNOLOGY; METABOLISM;

CELL LINE; GENE KNOCKOUT TECHNIQUES; HIV-1; HUMANS; INTERFERON-ALPHA; MYXOVIRUS RESISTANCE PROTEINS;

EID: 84961196397     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03146-15     Document Type: Article

References (36)

1. Mitchell PS, Emerman M, Malik HS. 2013. An evolutionary perspective on the broad antiviral specificity of MxA. Curr Opin Microbiol 16:493-499. http://dx.doi.org/10.1016/j.mib.2013.04.005.
2. Haller O, Kochs G. 2011. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 31:79-87. http://dx.doi.org/10.1089/jir.2010.0076.
3. Haller O, Staeheli P, Schwemmle M, Kochs G. 2015. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol 23:154-163. http://dx.doi.org/10.1016/j.tim.2014.12.003.
4. Melén K, Keskinen P, Ronni T, Sareneva T, Lounatmaa K, Julkunen I. 1996. Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope. J Biol Chem 271:23478-23486. http://dx.doi.org/10.1074/jbc.271.38.23478.
5. Aebi M, Fäh J, Hurt N, Samuel CE, Thomis D, Bazzigher L, Pavlovic J, Haller O, Staeheli P. 1989. cDNA structures and regulation of two interferon-induced human Mx proteins. Mol Cell Biol 9:5062-5072. http://dx.doi.org/10.1128/MCB.9.11.5062.
6. Haller O. 2013. Dynamins are forever: MxB inhibits HIV-1. Cell Host Microbe 14:371-373. http://dx.doi.org/10.1016/j.chom.2013.10.002.
7. Haller O, Gao S, von der Malsburg A, Daumke O, Kochs G. 2010. Dynamin-like MxA GTPase: structural insights into oligomerization and implications for antiviral activity. J Biol Chem 285:28419-28424. http://dx.doi.org/10.1074/jbc.R110.145839.
8. Faelber K, Gao S, Held M, Posor Y, Haucke V, Noé F, Daumke O. 2013. Oligomerization of dynamin superfamily proteins in health and disease. Prog Mol Biol Transl Sci 117:411-443. http://dx.doi.org/10.1016/B978-0-12-386931-9.00015-5.
9. Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, Cen S, Guo F, Liang C. 2013. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 14:398-410. http://dx.doi.org/10.1016/j.chom.2013.08.015.
10. Morlot S, Roux A. 2013. Mechanics of dynamin-mediated membrane fission. Annu Rev Biophys 42:629-649. http://dx.doi.org/10.1146/an nurev-biophys-050511-102247.
11. McNew JA, Sondermann H, Lee T, Stern M, Brandizzi F. 2013. GTPdependent membrane fusion. Annu Rev Cell Dev Biol 29:529-550. http://dx.doi.org/10.1146/annurev-cellbio-101512-122328.
12. Gao S, von der Malsburg A, Paeschke S, Behlke J, Haller O, Kochs G, Daumke O. 2010. Structural basis of oligomerization in the stalk region of dynamin-like MxA. Nature 465:502-506. http://dx.doi.org/10.1038/nature08972.
13. Pavlovic J, Zürcher T, Haller O, Staeheli P. 1990. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 64:3370-3375.
14. Xiao H, Killip MJ, Staeheli P, Randall RE, Jackson D. 2013. The human interferon-induced MxA protein inhibits early stages of influenza A virus infection by retaining the incoming viral genome in the cytoplasm. J Virol 87:13053-13058. http://dx.doi.org/10.1128/JVI.02220-13.
15. Matzinger SR, Carroll TD, Dutra JC, Ma Z-M, Miller CJ. 2013. Myxovirus resistance gene A (MxA) expression suppresses influenza A virus replication in alpha interferon-treated primate cells. J Virol 87:1150-1158. http://dx.doi.org/10.1128/JVI.02271-12.
16. Frese M, Kochs G, Meier-Dieter U, Siebler J, Haller O. 1995. Human MxA protein inhibits tick-borne Thogoto virus but not Dhori virus. J Virol 69:3904-3909.
17. Netherton CL, Simpson J, Haller O, Wileman TE, Takamatsu H-H, Monaghan P, Taylor G. 2009. Inhibition of a large double-stranded DNA virus by MxA protein. J Virol 83:2310-2320. http://dx.doi.org/10.1128/JVI.00781-08.
18. Li N, Zhang L, Chen L, Feng W, Xu Y, Chen F, Liu X, Chen Z, Liu W. 2012. MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen. Hepatology 56:803-811. http://dx.doi.org/10.1002/hep.25608.
19. Kochs G, Janzen C, Hohenberg H, Haller O. 2002. Antivirally active MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear complexes. Proc Natl Acad SciUSA99:3153-3158. http://dx.doi.org/10.1073/pnas.052430399.
20. Reichelt M, Stertz S, Krijnse-Locker J, Haller O, Kochs G. 2004. Missorting of LaCrosse virus nucleocapsid protein by the interferon-induced MxA GTPase involves smooth ER membranes. Traffic 5:772-784. http://dx.doi.org/10.1111/j.1600-0854.2004.00219.x.
21. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. http://dx.doi.org/10.1038/nature09907.
22. Goujon C, Moncorgé O, Bauby H, Doyle T, Ward CC, Schaller T, Hué S, Barclay WS, Schulz R, Malim MH. 2013. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 502:559-562. http://dx.doi.org/10.1038/nature12542.
23. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, Schoggins JW, Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD. 2013. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 502: 563-566. http://dx.doi.org/10.1038/nature12653.
24. Fricke T, White TE, Schulte B, de Souza Aranha Vieira DA, Dharan A, Campbell EM, Brandariz-Nuñez A, Diaz-Griffero F. 2014. MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology 11:68. http://dx.doi.org/10.1186/s12977-014-0068-x.
25. Goujon C, Moncorgé O, Bauby H, Doyle T, Barclay WS, Malim MH. 2014. Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor. J Virol 88:9017-9026. http://dx.doi.org/10.1128/JVI.01269-14.
26. Busnadiego I, Kane M, Rihn SJ, Preugschas HF, Hughes J, Blanco-Melo D, Strouvelle VP, Zang TM, Willett BJ, Boutell C, Bieniasz PD, Wilson SJ. 2014. Host and viral determinants of Mx2 antiretroviral activity. J Virol 88:7738-7752. http://dx.doi.org/10.1128/JVI.00214-14.
27. Matreyek KA, Wang W, Serrao E, Singh P, Levin HL, Engelman A. 2014. Host and viral determinants for MxB restriction of HIV-1 infection. Retrovirology 11:90. http://dx.doi.org/10.1186/s12977-014-0090-z.
28. Goujon C, Greenbury RA, Papaioannou S, Doyle T, Malim MH. 2015. A triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2. J Virol 89:4676-4680. http://dx.doi.org/10.1128/JVI.00169-15.
29. Schulte B, Buffone C, Opp S, Di Nunzio F, De Souza Aranha Vieira DA, Brandariz-Nuñez A, Diaz-Griffero F. 2015. Restriction of HIV-1 requires the N-terminal region of MxB as a capsid-binding motif but not as a nuclear localization signal. J Virol 89:8599-8610. http://dx.doi.org/10.1128/JVI.00753-15.
30. Lienlaf M, Hayashi F, Di Nunzio F, Tochio N, Kigawa T, Yokoyama S, Diaz-Griffero F. 2011. Contribution of E3-ubiquitin ligase activity to HIV-1 restriction by TRIM5 rh: structure of the RING domain of TRIM5. J Virol 85:8725-8737. http://dx.doi.org/10.1128/JVI.00497-11.
31. Diaz-Griffero F, Perron M, McGee-Estrada K, Hanna R, Maillard PV, Trono D, Sodroski J. 2008. A human TRIM5α B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology 378:233-242. http://dx.doi.org/10.1016/j.virol.2008.05.008.
32. Dominguez AA, Lim WA, Qi LS. 2016. Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol 17:5-15. http://dx.doi.org/10.1038/nrm.2015.2.
33. Fribourgh JL, Nguyen HC, Matreyek KA, Alvarez FJD, Summers BJ, Dewdney TG, Aiken C, Zhang P, Engelman A, Xiong Y. 2014. Structural insight into HIV-1 restriction by MxB. Cell Host Microbe 16:627-638. http://dx.doi.org/10.1016/j.chom.2014.09.021.
34. Buffone C, Schulte B, Opp S, Diaz-Griffero F. 2015. Contribution of MxB oligomerization to HIV-1 capsid binding and restriction. J Virol 89:3285-3294. http://dx.doi.org/10.1128/JVI.03730-14.
35. Goujon C, Malim MH. 2010. Characterization of the alpha interferoninduced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol 84:9254-9266. http://dx.doi.org/10.1128/JVI.00854-10.
36. Diaz-Griffero F, Qin XR, Hayashi F, Kigawa T, Finzi A, Sarnak Z, Lienlaf M, Yokoyama S, Sodroski J. 2009. A B-box 2 surface patch important for TRIM5 self-association, capsid binding avidity, and retrovirus restriction. J Virol 83:10737-10751. http://dx.doi.org/10.1128/JVI.01307-09.